Clinical Trials on Metastatic Castration Sensitive Prostate Cancer

Total 10818 results

Tceleron Therapeutics, Inc.

Terminated

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Peter MacCallum Cancer Centre, Australia

Completed

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)

Metastatic Castration Resistant Prostate Cancer

Australia
University of Utah
National Cancer Institute (NCI)

Recruiting

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Northwestern University
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Active, not recruiting

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Progressive Disease | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation... and other conditions

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic

Recruiting

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostatic Adenocarcinoma | Castration Levels of Testosterone

United States, Switzerland, Mexico, Chile, Colombia
Syntrix Biosystems, Inc.
National Cancer Institute (NCI)

Recruiting

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201)

Metastatic Castration-resistant Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United Kingdom, Netherlands, Finland
Fusion Pharmaceuticals Inc.

Recruiting

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST)

Metastatic Castration Resistant Prostate Cancer

United States
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Active, not recruiting

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

Japan
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Metastatic Castration-resistant Prostate Cancer

China
POINT Biopharma, a wholly owned subsidiary of Eli...

Active, not recruiting

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, Sweden, France, United Kingdom
Hinova Pharmaceuticals Aus Pty Ltd

Completed

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Australia
Dana-Farber Cancer Institute
Eli Lilly and Company; Genentech, Inc.

Active, not recruiting

Abemaciclib With or Without Atezolizumab for mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Australian and New Zealand Urogenital and Prostate...
Astellas Pharma Inc; Endocyte; Prostate Cancer Research Alliance; National Health...

Active, not recruiting

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)

Metastatic Castration-Resistant Prostate Cancer

Australia
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Metastatic Castration-resistant Prostate Cancer

United States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
Université de Sherbrooke
Canadian Cancer Society (CCS); Fonds de la Recherche en Santé du Québec; Merck... and other collaborators

Completed

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Canada
Tceleron Therapeutics, Inc.

Terminated

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Clovis Oncology, Inc.

Active, not recruiting

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

Prostate Cancer Metastatic

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.; Stand Up To Cancer

Active, not recruiting

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Metastatic Prostate Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetics of ODM-209 (STESIDES)

Advanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Finland, France, Denmark
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
Centre Georges Francois Leclerc

Not yet recruiting

Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration. (GaLuPro)

Patients With Metastatic Castration-resistant Prostate Cancer
Peter MacCallum Cancer Centre, Australia

Recruiting

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer (AlphaBet)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer

India
British Columbia Cancer Agency

Recruiting

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Canada
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Advanced Accelerator Applications

No longer available

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Metastatic Castration-resistant Prostate Cancer (mCRPC)
SL VAXiGEN

Recruiting

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Korea, Republic of
Yantai LNC Biotechnology Singapore PTE. LTD.

Not yet recruiting

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Metastatic Castration-resistant Prostate Cancer, mCRPC
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
University of Oklahoma
Dendreon

Recruiting

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (OUSCCEXCITE)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB)

Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Bayer

Active, not recruiting

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings (DEAR-EXT)

Non-metastatic Castration-resistant Prostate Cancer

United States
Bayer

Active, not recruiting

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States, United Kingdom, Finland
Bayer

Completed

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings (DEAR)

Non-metastatic Castration-resistant Prostate Cancer

United States
Accutar Biotechnology Inc

Terminated

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

China
Allarity Therapeutics
Smerud Medical Research International AS; Lantern Pharma Inc.

Active, not recruiting

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Metastatic Castration-Resistant Prostate Cancer Patients

Denmark
University of Washington
National Cancer Institute (NCI)

Terminated

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IV Prostate Cancer AJCC v7

United States
National Cancer Institute (NCI)

Terminated

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. (IRSTB030)

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer | Circulating Tumor Cells

Italy
Cancer Trials Ireland

Terminated

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. (DICE)

Metastatic Cancer | Bone Metastases | Castration-resistant Prostate Cancer

Ireland
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China

Clinical Trials on Metastatic Castration Sensitive Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations